<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832830</url>
  </required_header>
  <id_info>
    <org_study_id>IRON-1</org_study_id>
    <nct_id>NCT02832830</nct_id>
  </id_info>
  <brief_title>Image-guided and Intensity-modulated Radiotherapy Versus External Beam Radiotherapy for Patients With Spine Metastases</brief_title>
  <acronym>IRON-1</acronym>
  <official_title>Image-guided and Intensity-modulated Radiotherapy Versus External Beam Radiotherapy for Patients With Spine Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this explorative trial is to verify the comparability of a fractionated intensity&#xD;
      modulated radiotherapy with a conventional radiotherapy related to quality of life on the one&#xD;
      hand and to evaluate toxicity, re-calcification and stability of vertebral body as well as&#xD;
      pain relief and local response for palliative patients with painful spinal bone metastases on&#xD;
      the other hand. This is a single-center, prospective randomized controlled trial with&#xD;
      parallel-group design to determine the quality of life after RT in patients with spinal bone&#xD;
      metastases. Two different techniques were evaluated: intensity modulated radiotherapy (IMRT)&#xD;
      and fractionated conventional external beam RT with 10×3 Gy each.&#xD;
&#xD;
      Experimental intervention:&#xD;
&#xD;
      IMRT 10 x 3 Gy&#xD;
&#xD;
      Control intervention:&#xD;
&#xD;
      3D-RT 10 x 3 Gy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this explorative trial is to verify the comparability of a fractionated intensity&#xD;
      modulated radiotherapy with a conventional radiotherapy related to quality of life on the one&#xD;
      hand and to evaluate toxicity, re-calcification and stability of vertebral body as well as&#xD;
      pain relief and local response for palliative patients with painful spinal bone metastases on&#xD;
      the other hand. This is a single-center, prospective randomized controlled trial with&#xD;
      parallel-group design to determine the quality of life after RT in patients with spinal bone&#xD;
      metastases. Two different techniques were evaluated: intensity modulated radiotherapy (IMRT)&#xD;
      and fractionated conventional external beam RT with 10×3 Gy each.&#xD;
&#xD;
      Experimental intervention:&#xD;
&#xD;
      IMRT 10 x 3 Gy&#xD;
&#xD;
      Control intervention:&#xD;
&#xD;
      3D-RT 10 x 3 Gy After the baseline measurements have been recorded, the patients will be&#xD;
      randomly assigned to one of the two groups: IMRT 10×3 Gy (n = 30) or fractionated&#xD;
      conventional 3D-RT 10×3 Gy (n = 30). The RT will be applied daily (mondy to Friday).&#xD;
&#xD;
      Follow-up per patient:&#xD;
&#xD;
      The target parameters will be measured and recorded at baseline, at the end of RT (t1), and&#xD;
      at 12 weeks (t2) and 6 months (t3) after the end of the irradiation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>3-months-time-point after the end of RT</time_frame>
    <description>improvement of more than 10% according to the EORTC BM22 questionaire measured at the 3-months-time-point after the end of RT (t2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone density</measure>
    <time_frame>12 weeks post completion radiotherapy</time_frame>
    <description>bone density is assessed 12 weeks post completion of radiotherapy using follow-up CT scan of the spine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain reduction</measure>
    <time_frame>end of treatment, 12 and 24 weeks post completion of radiotherapy</time_frame>
    <description>pain is evaluated using the VAS pain scale (0-100 points) at completion and 12/ 24 weeks post completion of radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>12 and 24 weeks post completion of therapy</time_frame>
    <description>Fatigue is assessed using the EORTC FA13 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vertebral Bony Metastases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intensity modulated radiotherapy (IMRT) 10 x 3 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fractionated conventional external beam RT 10×3 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fractionated RT</intervention_name>
    <description>external beam Radiotherapy of the involved spinal bone metastasis</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologically confirmed tumor diagnosis and with secondary diagnosed&#xD;
             solitary/multiple spinal bone metastases&#xD;
&#xD;
          -  Indication for RT of the spinal bone metastases&#xD;
&#xD;
          -  Age of between 18 and 85 years&#xD;
&#xD;
          -  Karnofsky index of at least 50&#xD;
&#xD;
          -  Signed declaration of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphoma&#xD;
&#xD;
          -  Significant neurological or psychiatric disorders, including dementia and epileptic&#xD;
             seizures&#xD;
&#xD;
          -  Previous RT at the current irradiation site&#xD;
&#xD;
          -  Other severe disorders that in the judgment of the study director may prevent the&#xD;
             patient's participation in the study&#xD;
&#xD;
          -  Lacking or diminished legal capacity&#xD;
&#xD;
          -  Any medical of psychological condition that the study director considers a preventive&#xD;
             factor for the patient's ability to complete the study or to adequately understand the&#xD;
             scope of the study and to give his or her consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harald Rief, MD, PhD</last_name>
    <email>harald.rief@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jürgen Debus, MD, PhD</last_name>
    <email>juergen.debus@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Radiation Oncology, University of Heidelberg, Germany</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Chung Y, Yoon HI, Kim JH, Nam KC, Koom WS. Is helical tomotherapy accurate and safe enough for spine stereotactic body radiotherapy? J Cancer Res Clin Oncol. 2013 Feb;139(2):243-8. doi: 10.1007/s00432-012-1321-0. Epub 2012 Oct 2.</citation>
    <PMID>23052695</PMID>
  </results_reference>
  <results_reference>
    <citation>Katsoulakis E, Riaz N, Cox B, Mechalakos J, Zatcky J, Bilsky M, Yamada Y. Delivering a third course of radiation to spine metastases using image-guided, intensity-modulated radiation therapy. J Neurosurg Spine. 2013 Jan;18(1):63-8. doi: 10.3171/2012.9.SPINE12433. Epub 2012 Oct 26.</citation>
    <PMID>23101946</PMID>
  </results_reference>
  <results_reference>
    <citation>Murai T, Murata R, Manabe Y, Sugie C, Tamura T, Ito H, Miyoshi Y, Shibamoto Y. Intensity modulated stereotactic body radiation therapy for single or multiple vertebral metastases with spinal cord compression. Pract Radiat Oncol. 2014 Nov-Dec;4(6):e231-7. doi: 10.1016/j.prro.2014.02.005. Epub 2014 Mar 31.</citation>
    <PMID>25407874</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):594-605. Review.</citation>
    <PMID>12573746</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bony metastases</keyword>
  <keyword>palliative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

